Currus Biologics, a biotechnology company focused on improving lives by developing CAR T-cell therapy for solid tumour indications using its BEAT technology, announced today that its Chief Executive Officer, Sam Cobb, has been invited to present at the 7th CAR -TCR Summit in Boston 19-22 September 2022.

Presentation details

Time and Date: Wednesday 21 September 16:30 The Next Frontier: Enhancing functional CAR T-cell activity.

Presentation Topic: BEAT Technology to Enhance CAR-T Cell Therapy in the Solid Tumor Setting

• Overcoming problems of persistence, the immune suppressive tumor microenvironment and antigen loss through the addition of a BEAT or bi-specific engager of antigen presenting cells and T-cells, to CAR-T cell therapy; and

• Preclinical evidence demonstrates the therapeutic potential of the use of the BEAT in addition to CAR-T cell therapy for the treatment of solid tumors.

Sam Cobb will highlight Currus Biologics’ innovative BEAT technology and preclinical demonstration of the mechanism of action to improve CAR T-cell function.

“I am excited to present at this year’s CAR-TCR Summit and demonstrate how Currus is overcoming the challenges seen in the solid tumour setting with its novel BEAT platform” said Sam Cobb, CEO of Currus Biologics.

The CAR-TCR Summit is the industry’s trusted, definitive, end-to-end forum for the global network of autologous and allogeneic cell therapy drug developers.

Further details of the CAR-TCR summit can be found at: https://car-tcr-summit.com

Come and meet with us in person to discuss the BEAT technology.

Or please email us at info@currusbio.com